9. Berthet,C., Klarmann,K.D., Hilton,M.B., Suh,H.C., Keller,J.R., Kiyokawa,H., & Kaldis,P. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev. Cell 10, 563-573 (2006).
10. Borg,A., Sandberg,T., Nilsson,K., Johannsson,O., Klinker,M., Masback,A., Westerdahl,J., Olsson,H., & Ingvar,C. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J. Natl. Cancer Inst. 92, 1260-1266 (2000).
11. Brantley,M.A., Jr. & Harbour,J.W. The molecular biology of retinoblastoma. Ocul. Immunol. Inflamm. 9, 1-8 (2001).
12. Buchkovich,K., Duffy,L.A., & Harlow,E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58, 1097-1105 (1989).
13. Buschges,R., Weber,R.G., Actor,B., Lichter,P., Collins,V.P., &
Reifenberger,G. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol. 9, 435-442 (1999).
14. Canela,N., Orzaez,M., Fucho,R., Mateo,F., Gutierrez,R., Pineda-Lucena,A., Bachs,O., & Perez-Paya,E. Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A. J. Biol. Chem. 281, 35942-35953 (2006).
15. Chen,P.L., Scully,P., Shew,J.Y., Wang,J.Y., & Lee,W.H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58, 1193-1198 (1989).
16. Chudakov,D.M., Verkhusha,V.V., Staroverov,D.B., Souslova,E.A., Lukyanov,S., & Lukyanov,K.A. Photoswitchable cyan fluorescent protein for protein tracking. Nat. Biotechnol. 22, 1435-1439 (2004).
17. Classon,M. & Dyson,N. p107 and p130: versatile proteins with interesting pockets. Exp. Cell Res. 264, 135-147 (2001).
18. Day,R.N. & Schaufele,F. Imaging molecular interactions in living cells.
Mol. Endocrinol. 19, 1675-1686 (2005).
19. Dealy,M.J., Nguyen,K.V., Lo,J., Gstaiger,M., Krek,W., Elson,D., Arbeit,J., Kipreos,E.T., & Johnson,R.S. Loss of Cul1 results in early embryonic lethality and dysregulation of cyclin E. Nat. Genet. 23, 245-248 (1999).
20. DeCaprio,J.A., Ludlow,J.W., Lynch,D., Furukawa,Y., Griffin,J., Piwnica-Worms,H., Huang,C.M., & Livingston,D.M. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58, 1085-1095 (1989).
21. Delmer,A., Ajchenbaum-Cymbalista,F., Tang,R., Ramond,S., Faussat,A.M., Marie,J.P., & Zittoun,R. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 85, 2870-2876 (1995).
22. Denner,P., Schmalowsky,J., & Prechtl,S. High-content analysis in preclinical drug discovery. Comb. Chem. High Throughput. Screen. 11, 216-230 (2008).
23. Desai,D., Wessling,H.C., Fisher,R.P., & Morgan,D.O. Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. Mol. Cell Biol.
15, 345-350 (1995).
24. Deshpande,A., Sicinski,P., & Hinds,P.W. Cyclins and cdks in development and cancer: a perspective. Oncogene 24, 2909-2915 (2005).
25. Diehl,J.A., Cheng,M., Roussel,M.F., & Sherr,C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.
Genes Dev. 12, 3499-3511 (1998).
26. Diehl,J.A., Zindy,F., & Sherr,C.J. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11, 957-972 (1997).
27. Doisneau-Sixou,S.F., Sergio,C.M., Carroll,J.S., Hui,R., Musgrove,E.A., &
Sutherland,R.L. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr. Relat Cancer 10, 179-186 (2003).
28. Donjerkovic,D. & Scott,D.W. Regulation of the G1 phase of the mammalian cell cycle. Cell Res. 10, 1-16 (2000).
29. Doree,M. & Galas,S. The cyclin-dependent protein kinases and the control of cell division. FASEB J. 8, 1114-1121 (1994).
30. Dowdy,S.F., Hinds,P.W., Louie,K., Reed,S.I., Arnold,A., & Weinberg,R.A.
Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73, 499-511 (1993).
31. Ekholm,S.V. & Reed,S.I. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol. 12, 676-684 (2000).
32. Erlandsson,F., Wahlby,C., Ekholm-Reed,S., Hellstrom,A.C., Bengtsson,E., & Zetterberg,A. Abnormal expression pattern of cyclin E in tumour cells. Int. J. Cancer 104, 369-375 (2003).
33. Ewen,M.E., Sluss,H.K., Sherr,C.J., Matsushime,H., Kato,J., &
Livingston,D.M. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73, 487-497 (1993).
34. Felix,M.A., Labbe,J.C., Doree,M., Hunt,T., & Karsenti,E. Triggering of cyclin degradation in interphase extracts of amphibian eggs by cdc2 kinase.
Nature 346, 379-382 (1990).
35. Franek,F., Strnad,M., Havlicek,L., Siglerova,V., Fismolova,I., &
Eckschlager,T. Diverse effects of the cyclin-dependent kinase inhibitor bohemine: Concentration- and time-dependent suppression or stimulation of hybridoma culture. Cytotechnology 36, 117-123 (2001).
36. Germain,D., Russell,A., Thompson,A., & Hendley,J. Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286. J. Biol. Chem.
275, 12074-12079 (2000).
37. Gillett,C.E. & Barnes,D.M. Demystified ... cell cycle. Mol. Pathol. 51, 310-316 (1998).
38. Glotzer,M., Murray,A.W., & Kirschner,M.W. Cyclin is degraded by the ubiquitin pathway. Nature 349, 132-138 (1991).
39. Goodrich,D.W. & Lee,W.H. Molecular characterization of the retinoblastoma susceptibility gene. Biochim. Biophys. Acta 1155, 43-61 (1993).
40. Grana,X., Garriga,J., & Mayol,X. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene 17, 3365-3383 (1998).
41. Hinds,P.W., Mittnacht,S., Dulic,V., Arnold,A., Reed,S.I., & Weinberg,R.A.
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70, 993-1006 (1992).
42. Hochegger,H., Takeda,S., & Hunt,T. Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat. Rev. Mol. Cell Biol. 9, 910-916 (2008).
43. Honda,R., Lowe,E.D., Dubinina,E., Skamnaki,V., Cook,A., Brown,N.R., &
Johnson,L.N. The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles. EMBO J. 24, 452-463 (2005).
44. Hunter,T. & Karin,M. The regulation of transcription by phosphorylation. Cell 70, 375-387 (1992).
45. Johannesdottir,G., Gudmundsson,J., Bergthorsson,J.T., Arason,A., Agnarsson,B.A., Eiriksdottir,G., Johannsson,O.T., Borg,A., Ingvarsson,S., Easton,D.F., Egilsson,V., & Barkardottir,R.B. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res. 56, 3663-3665 (1996).
46. Johnson,D.G. & Walker,C.L. Cyclins and cell cycle checkpoints. Annu.
Rev. Pharmacol. Toxicol. 39, 295-312 (1999).
47. Johnson,K., Liu,L., Majdzadeh,N., Chavez,C., Chin,P.C., Morrison,B., Wang,L., Park,J., Chugh,P., Chen,H.M., & D'Mello,S.R. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs. J. Neurochem. 93, 538-548 (2005).
48. Johnston,P.A. & Johnston,P.A. Cellular platforms for HTS: three case studies. Drug Discov. Today 7, 353-363 (2002).
49. Juillerat,A., Gronemeyer,T., Keppler,A., Gendreizig,S., Pick,H., Vogel,H.,
& Johnsson,K. Directed evolution of O6-alkylguanine-DNA alkyltransferase for efficient labeling of fusion proteins with small molecules in vivo. Chem.
Biol. 10, 313-317 (2003).
50. Kaldis,P. The cdk-activating kinase (CAK): from yeast to mammals. Cell Mol. Life Sci. 55, 284-296 (1999).
51. Keppler,A., Gendreizig,S., Gronemeyer,T., Pick,H., Vogel,H., &
Johnsson,K. A general method for the covalent labeling of fusion proteins with small molecules in vivo. Nat. Biotechnol. 21, 86-89 (2003).
52. Khatib,Z.A., Matsushime,H., Valentine,M., Shapiro,D.N., Sherr,C.J., &
Look,A.T. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 53, 5535-5541 (1993).
53. Knudsen,E.S. & Wang,J.Y. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J. Biol. Chem. 271, 8313-8320 (1996).
54. Knudsen,K.E., Cavenee,W.K., & Arden,K.C. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability.
Cancer Res. 59, 2297-2301 (1999).
55. Knudsen,K.E., Diehl,J.A., Haiman,C.A., & Knudsen,E.S. Cyclin D1:
polymorphism, aberrant splicing and cancer risk. Oncogene 25, 1620-1628 (2006).
56. Koepp,D.M., Schaefer,L.K., Ye,X., Keyomarsi,K., Chu,C., Harper,J.W., &
Elledge,S.J. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294, 173-177 (2001).
57. Korenjak,M. & Brehm,A. E2F-Rb complexes regulating transcription of genes important for differentiation and development. Curr. Opin. Genet.
Dev. 15, 520-527 (2005).
58. LaBaer,J., Garrett,M.D., Stevenson,L.F., Slingerland,J.M., Sandhu,C., Chou,H.S., Fattaey,A., & Harlow,E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11, 847-862 (1997).
59. Lammie,G.A., Fantl,V., Smith,R., Schuuring,E., Brookes,S., Michalides,R., Dickson,C., Arnold,A., & Peters,G. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6, 439-444 (1991).
60. Lee,J.O., Russo,A.A., & Pavletich,N.P. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391, 859-865 (1998).
61. Leibundgut,K., Schmitz,N.M., & Hirt,A. Catalytic activities of G1 cyclin-dependent kinases and phosphorylation of retinoblastoma protein in mobilized peripheral blood CD34+ hematopoietic progenitor cells. Stem Cells 23, 1002-1011 (2005).
62. Leone,G., DeGregori,J., Sears,R., Jakoi,L., & Nevins,J.R. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387, 422-426 (1997).
63. Lippincott-Schwartz,J., Altan-Bonnet,N., & Patterson,G.H.
Photobleaching and photoactivation: following protein dynamics in living cells. Nat. Cell Biol. Suppl, S7-14 (2003).
64. Lippincott-Schwartz,J., Snapp,E., & Kenworthy,A. Studying protein dynamics in living cells. Nat. Rev. Mol. Cell Biol. 2, 444-456 (2001).
65. Loughran,O. & La Thangue,N.B. E2F proteins. Curr. Biol. 12, R377 (2002).
66. Lu,F., Gladden,A.B., & Diehl,J.A. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 63, 7056-7061 (2003).
67. Ludlow,J.W., Glendening,C.L., Livingston,D.M., & DeCarprio,J.A.
Specific enzymatic dephosphorylation of the retinoblastoma protein. Mol.
Cell Biol. 13, 367-372 (1993).
68. Lundberg,A.S. & Weinberg,R.A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell Biol. 18, 753-761 (1998).
69. MacCallum,D.E., Melville,J., Frame,S., Watt,K., Anderson,S., Gianella-Borradori,A., Lane,D.P., & Green,S.R. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65, 5399-5407 (2005).
70. MacLachlan,T.K., Somasundaram,K., Sgagias,M., Shifman,Y., Muschel,R.J., Cowan,K.H., & El Deiry,W.S. BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression. J. Biol.
Chem. 275, 2777-2785 (2000).
71. Malumbres,M. & Barbacid,M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 1, 222-231 (2001).